ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04^®, the company’s phase 2 Alzheimer’s candidate.

“This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering from this devastating condition.”

The SBIR program is one of the most competitive NIH funding initiatives, designed to support small businesses advancing cutting-edge science with high commercial potential.

“The NIH’s support underscores the strength of our science and alongside our UK ILAP designation (conditional market approval after phase 2) and EU CTAs validates AD04^® as a global program. This award positions us to accelerate regulatory momentum and attract the strategic partners required for broad patient access,” said Jeffrey Madden, Co-Founder and CEO.

This news follows the recent publication of encouraging AD04^® results in The Journal of Prevention of Alzheimer’s Disease (JPAD) https://pubmed.ncbi.nlm.nih.gov/40953123/. The publication highlighted encouraging results from AD04’s earlier Phase 2 trial. A follow-up independent statistical analysis confirmed that the positive effects seen in patients were reliable and not due to chance. These findings suggest that AD04 produced a treatment effect that compared favorably to monoclonal Alzheimer’s therapies already on the market, while being easier to take, safer, and more affordable.